Acute Promyelocytic Leukemia Clinical Trials

3 recruiting

Acute Promyelocytic Leukemia Trials at a Glance

7 actively recruiting trials for acute promyelocytic leukemia are listed on ClinicalTrialsFinder across 6 cities in 17 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Houston, Bari, and Beijing. Lead sponsors running acute promyelocytic leukemia studies include M.D. Anderson Cancer Center, Associazione Italiana Ematologia Oncologia Pediatrica, and Instituto do Cancer do Estado de São Paulo.

Browse acute promyelocytic leukemia trials by phase

Treatments under study

About Acute Promyelocytic Leukemia Clinical Trials

Looking for clinical trials for Acute Promyelocytic Leukemia? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Acute Promyelocytic Leukemia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Acute Promyelocytic Leukemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 1

PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid LeukemiaAcute Promyelocytic Leukemia With PML-RARA
M.D. Anderson Cancer Center77 enrolled1 locationNCT02390635
Recruiting
Phase 3

Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia

Acute Promyelocytic Leukemia (APL)
Quetzal Therapeutics150 enrolled4 locationsNCT07504458
Recruiting
Phase 2

Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

Acute Promyelocytic Leukemia With PML-RARA
M.D. Anderson Cancer Center151 enrolled5 locationsNCT01409161
Recruiting
Phase 2

Frontline Oral Arsenic Trioxide for APL

Acute Promyelocytic Leukemia
The University of Hong Kong100 enrolled2 locationsNCT04687176
Recruiting
Phase 2

Oral Arsenic With ATRA for Newly Diagnosed Patients With Acute Promyelocytic Leukemia

Acute Promyelocytic Leukemia (APL)
Instituto do Cancer do Estado de São Paulo115 enrolled1 locationNCT06982274
Recruiting
Not Applicable

Optimum Induction Therapy of Low-risk APL

Acute Promyelocytic LeukemiaInduction TherapyOral
Peking University People's Hospital74 enrolled1 locationNCT05832320
Recruiting
Phase 2

Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia

Acute Promyelocytic Leukemia
Associazione Italiana Ematologia Oncologia Pediatrica89 enrolled31 locationsNCT04793919